Added to YB: 2026-01-19
Pitch date: 2026-01-15
ABVX [neutral]
ABIVAX Société Anonyme
-0.78%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 8.4B
Pitch Price
EUR 103.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-36.34
P/E
-24.19
EV/Sales
1.5K
Sector
Biotechnology
Category
growth
Abivax (ABVX France): 2026 a defining year for obefazimod and the broader platform
ABVX (update): Obefazimod Phase 3 UC maintenance data due late Q2 2026, US filing later 2026. 80%+ patients completed 44-week study, no new safety signals. Positioned as bridge therapy between conventional/biologics vs head-to-head competition. Crohn's Phase 2b end-2026. Cash to Q4 2027.
Read full article (2 min)